U.S. Healthcare Services Stock News

NYSE:UNM
NYSE:UNMInsurance

Unum (UNM) Stock Gains Ground Despite Softer Margins And Premium P E

The market finally cut Unum Group some slack today. After drifting lower over the past month, the stock is up about 2% in live trading as investors digest a Q2 report that leans firmly on earnings power rather than headline revenue. The core message is simple. Adjusted operating earnings per share of US$2.16 and a consolidated adjusted operating return on equity near 15.9% give bulls fresh ammunition, even as recent net profit margins over the last year sit well below the prior year. The...
NasdaqGS:ARM
NasdaqGS:ARMSemiconductor

Arm (ARM) Stock Looks Undervalued But Far From A Bargain

Arm Holdings stock has surged 96.0% year to date, yet its low value score suggests the current price does not screen as a clear bargain on the broader checks. Year to date, Arm Holdings has gained 96.0%, which sets a high bar for any further upside to be justified by fundamentals. Strong positioning in AI servers and royalty growth can support higher earnings expectations, while recent share price volatility and concerns around smartphone demand may limit how much investors are willing to...
NYSE:NBR
NYSE:NBREnergy Services

Nabors Industries (NBR) Stock Rises On Margin Strength Despite Thin Cash Flow

Nabors Industries stock is edging higher today, up about 2% in active trading, even though the fresh quarter again showed a loss at the earnings per share line. The market is reacting less to that headline loss and more to what sat behind it. Adjusted earnings before interest, tax, depreciation and amortization came in at roughly US$222 million with margins above 27%, ahead of management’s own targets. For a stock that has fallen over the past quarter, investors are now weighing that stronger...
NasdaqGS:RELY
NasdaqGS:RELYDiversified Financial

Is Remitly’s All‑in‑One Global Card and USDC Platform Altering The Investment Case For Remitly Global (RELY)?

Earlier this year, Remitly Global, Inc. launched the Remitly Global Card, a cross-border account that lets customers get paid, spend, save, and send money internationally from one platform, with features such as preferred FX rates, no foreign transaction fees, global ATM access, multi-currency and USDC balances, and instant card-to-card transfers. A distinctive angle is Remitly Global Card Membership, which pairs access to an open-end line of credit and Smart Rate FX protection with perks...
NYSE:RNG
NYSE:RNGSoftware

AI Stocks To Watch As Enterprise Software Spending Shifts Toward Automation

Artificial intelligence stocks sit at the crossroads of several forces that investors are watching in 2026. Global growth signals are mixed, central banks continue to weigh inflation data, and energy costs remain a key swing factor. At the same time, demand for AI related chips, software, cloud and large language models links into real investment and trade flows across the US, Europe and Asia. This article uses an AI Stocks screener focused on companies directly involved in the ChatGPT and...
NasdaqGS:DXPE
NasdaqGS:DXPETrade Distributors

DXP Enterprises (DXPE) Falls Before Earnings, Is The 6% Discount Enough?

DXP Enterprises (DXPE) shares declined 7.54% in the latest session, lagging the S&P 500 and industrial peers as investors focused on the company’s upcoming earnings report and what it might reveal about demand trends. See our latest analysis for DXP Enterprises. The recent 1 day share price decline of 7.54% and 7 day share price decline of 14.13% follow a strong year to date share price return of 37.56%. The 5 year total shareholder return of 369.37% highlights the impact of longer term...
NYSE:SUI
NYSE:SUIResidential REITs

Why Sun Communities (SUI) Is Up 6.9% After Beating Core FFO Guidance And Announcing $1B Buyback

Sun Communities, Inc. has now reported its second-quarter 2026 results, with sales of US$422.7 million and revenue of US$484.6 million, but a net loss of US$992.7 million that translated into a basic loss per share of US$8.06. Beneath the headline loss, the company delivered core funds from operations of US$1.84 per share above guidance, raised its full-year outlook, authorized a US$1 billion share repurchase program, and completed the sale of its U.K. business to concentrate on its North...
NYSE:TYL
NYSE:TYLSoftware

Tyler Technologies (TYL) Beat Q2 And Expanded Buybacks, Is The Stock Above Fair Value?

Tyler Technologies (TYL) is in focus after reporting second quarter 2026 results and updating investors on a sizable share repurchase program, providing fresh data points to assess the stock. See our latest analysis for Tyler Technologies. The earnings beat and expanded buyback plan have come after a mixed stretch for Tyler Technologies, with a 17.3% 7 day share price return and its 1 year total shareholder return down 39.87% at a recent price of $333.50. That pattern suggests short term...
NYSE:CWEN
NYSE:CWENRenewable Energy

Clearway Energy (CWEN) Faces An Earnings Test Following An Undervalued Narrative

Clearway Energy earnings expectations set the tone Clearway Energy (CWEN) is in focus as investors watch for June 2026 quarterly results, with expectations for lower earnings alongside higher revenue. These results could influence how the stock trades in the near term. See our latest analysis for Clearway Energy. Clearway Energy’s recent share price performance has been weak, with the stock down 23.74% on a 90 day share price return basis, even though the 3 year total shareholder return is...
NasdaqGS:ARWR
NasdaqGS:ARWRBiotechs

Arrowhead Pharmaceuticals (ARWR) Could Be 3% Undervalued On Late Stage Trial Progress

Arrowhead Pharmaceuticals (ARWR) is back in focus after two late stage RNA interference programs hit important milestones. Plozasiran delivered positive Phase 3 topline data in severe hypertriglyceridemia, and zodasiran’s Phase 3 YOSEMITE trial has now completed enrollment. See our latest analysis for Arrowhead Pharmaceuticals. The recent late stage cardiometabolic data appear to be feeding into Arrowhead Pharmaceuticals’ share price momentum, with a 30 day share price return of 7.11% and a...
NYSE:CUBE
NYSE:CUBESpecialized REITs

CubeSmart (CUBE) Reaffirms Its Dividend, Is The Stock Still Undervalued?

CubeSmart (CUBE) has reaffirmed its income return profile, with the Board of Trustees declaring a quarterly dividend of $0.53 per common share for the period ending September 30, 2026. See our latest analysis for CubeSmart. The reaffirmed dividend sits alongside a steady pick up in CubeSmart's share price momentum, with a 7 day share price return of 3.19% and a year to date share price return of 19.86%, while the 1 year total shareholder return is 9.09%. If CubeSmart's steady income and price...
NYSE:PCOR
NYSE:PCORSoftware

Guidewire Stock And 2 Software Picks Tied To The AI Spending Debate

Big tech’s heavy spending on artificial intelligence is suddenly under the microscope after Meta shares dropped 11% on plans to lift annual spending to as much as US$145b, even as quarterly profit fell 14% to US$6b and free cash flow slid to a five year low of US$784 million. With Google also facing questions around the pay off from high AI budgets, many investors are rethinking which companies might benefit or struggle as this theme plays out. This article looks at three business...
NasdaqGS:AGYS
NasdaqGS:AGYSSoftware

July 2026's Top Value Stocks With Estimated Discounted Prices

Over the last 7 days, the United States market has experienced a 2.6% drop, yet it remains up by 14% over the past year with earnings forecasted to grow by 17% annually. In this environment, identifying undervalued stocks can be a strategic approach for investors seeking opportunities where current prices may not fully reflect future growth potential.
NasdaqGM:RUM
NasdaqGM:RUMInteractive Media and Services

Top Growth Companies With Insider Ownership In July 2026

Over the last 7 days, the United States market has experienced a 2.6% drop, yet it remains up by 14% over the past year with earnings forecasted to grow by 17% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business and potential alignment of interests between management and shareholders.
NasdaqCM:YIBO
NasdaqCM:YIBOCommercial Services

3 Promising Penny Stocks With Market Caps Up To $200M

Over the last 7 days, the U.S. market has dropped 2.6%, but it has risen by 14% over the past year, with earnings projected to grow annually by 17% in the coming years. In light of these conditions, investors may find value in penny stocks—an investment area that still holds relevance despite being an older term. By focusing on companies with solid financials and potential for growth, investors can uncover opportunities among smaller or less-established firms that might offer both stability...
NYSE:AMC
NYSE:AMCEntertainment

AMC (AMC) Is Up 22.2% After Record Revenue and IMAX Hit Spotlight Premium Format Strategy

In the second quarter of 2026, AMC Entertainment Holdings reported revenue of US$1,596.7 million, up from US$1,397.9 million a year earlier, while its net loss widened to US$11.4 million and basic loss per share from continuing operations moved to US$0.02. The company also highlighted the exceptional performance of “The Odyssey,” which delivered the strongest two-week IMAX run in history, underscoring how premium formats and sold-out high-end showtimes are becoming a critical driver of...
NYSE:BWXT
NYSE:BWXTAerospace & Defense

Is BWX Technologies (BWXT) Priced For Perfection After A 215% Run?

BWX Technologies has delivered a very strong run over the last five years, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiple checks currently point to the stock trading at a premium to those fundamentals. BWX Technologies has returned 215.2% over five years, which sets a high bar for any further upside to be supported by fundamentals. The company’s valuation can be supported by expectations for continued cash flow generation from its core defense and...
NasdaqGS:UTHR
NasdaqGS:UTHRBiotechs

Is United Therapeutics (UTHR) Undervalued After Its Phase 3 Ralinepag Results?

United Therapeutics (UTHR) stock is in focus after the company reported statistically significant phase 3 ADVANCE OUTCOMES results for its investigational PAH therapy ralinepag, with full data recently published in The Lancet. See our latest analysis for United Therapeutics. The latest ralinepag data and board appointment of Dr. Victor Dzau come as United Therapeutics trades at US$524.70, with the share price return up 5.63% year to date but the 90-day share price return down 8.16%. Over a...
NYSE:CB
NYSE:CBInsurance

Chubb (CB) Stock Looks Reasonable On Earnings While Fair Value Looks Strong

Chubb stock has delivered a strong 126.4% total return over the past 5 years, yet the current checks send a mixed message, with the Excess Returns intrinsic value estimate suggesting the shares trade at a sizeable discount while the broader valuation framework does not flag the stock as an obvious bargain. Over 5 years, Chubb has returned 126.4%, which puts recent share price strength at the center of any valuation discussion. Future expectations for underwriting quality and capital...
NYSE:HOG
NYSE:HOGAuto

Harley-Davidson (HOG) Is Down 10.1% After Earnings Drop While Buybacks Continue - What's Changed

In July 2026, Harley-Davidson, Inc. reported that second-quarter net income fell to US$79.81 million from US$107.57 million a year earlier, with first-half net income dropping to US$104.58 million from US$240.67 million, while continuing to execute its share repurchase program. Despite the weaker earnings, Harley-Davidson has completed repurchases totaling 24,470,194 shares for about US$1.33 billion since July 2024, signaling ongoing capital returns even as profitability softens. Next, we’ll...
NYSE:FMC
NYSE:FMCChemicals

FMC (FMC) Reported Lower Sales And A Loss, Is It Still 37% Undervalued?

FMC earnings jolt investor focus FMC (FMC) is in the spotlight after reporting second quarter 2026 results that showed lower sales and a move from profit to loss, alongside updated revenue guidance pointing to a full year decline. See our latest analysis for FMC. The earnings miss and lower full year revenue guidance have come alongside heavy selling in FMC, with the share price down 8.5% on the day of the report and the 1 year total shareholder return falling 74.9%. This hints at fading...
NYSE:OMC
NYSE:OMCMedia

Omnicom (OMC) Stock Drops As Profit Strength Meets Integration Strain

Omnicom Group walked into this earnings print with the stock quietly grinding higher in recent weeks. Today that calm broke. Shares were down about 4% intraday after the release, even as the core advertising and marketing engine delivered a sharp earnings punch. The headline this quarter is profit power, not top line drama. Non GAAP adjusted earnings per share landed at US$2.65, and core adjusted EBITA margin sat near 17.8%. That is the story the market is wrestling with: a lower share price...
NasdaqGS:ONB
NasdaqGS:ONBBanks

Should ONB’s Strong Q2 Earnings and Buyback Shift How Old National Bancorp (ONB) Investors Act?

Old National Bancorp recently reported second-quarter 2026 results, with net interest income of US$578.99 million, net income of US$253.41 million, diluted EPS of US$0.65, net charge-offs of US$32.2 million, and completion of a buyback totaling 5,148,549 shares for US$123.5 million. This combination of higher earnings, stable credit costs, and active capital return gives investors fresh information on the bank’s current profitability and balance sheet management. We’ll now assess how this...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Is Stronger Rezdiffra Momentum and New Patents Altering The Investment Case For Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals, Inc. has reported past second-quarter 2026 results showing a net loss of US$57.94 million and basic and diluted loss per share of US$1.99, widening from US$42.28 million and US$1.50 per share a year earlier, despite beating analyst expectations on earnings and revenue. Alongside this, the company highlighted growing Rezdiffra sales in MASH, new patents extending protection for resmetirom, and the start of Phase 1 testing for its oral GLP-1 candidate MGL-2086 aimed...